Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.

Wendy BernhardKris BarretoAyman El-SayedCarolina GonzalezRaja Solomon ViswasDarien ToledoAngel CasacoJohn DeCoteauHumphrey FongeClarence Ronald Geyer

Published in: BMC cancer (2021)

Here, we show preclinical studies demonstrating that nimotuzumab conjugated to IRDye800CW is safe and does not exhibit toxicities commonly associated with EGFR targeting antibodies.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
drug delivery
tyrosine kinase
cancer therapy
photodynamic therapy
case control
cell therapy
double blind
stem cells